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ABSTRACT 
4-((benzyloxy) amino)-2-hydroxy-4-oxobutanoic acid which is a succinamic acid derivative has been synthesized in 3 step reaction with 
malic acid. Its structure confirmation was done by various techniques like 1H NMR, 13C NMR, & HRMS and is recently proposed as an 
insulinotropic agent for the treatment of non-insulin dependent diabetes mellitus. In the present study, the effect of 4-((benzyloxy) amino)-
2-hydroxy-4-oxobutanoic acid on plasma glucose, serum insulin, serum lipid profile and lipid peroxidation in streptozotocin–nicotinamide 
induced type 2 diabetic model was investigated.  4-((benzyloxy) amino)-2-hydroxy-4-oxobutanoic acid was administered orally (20 mg/kg 
b.w.) to streptozotocin + nicotinamide (STZ + NAD) induced diabetic rats for 28 days. A significant increase in fasting blood glucose levels, 
HbA1c levels, Serum lipid profile (TG & TC) and in  the levels of Malonaldialdehyde (MDA, end product of lipid peroxidation) was observed in 
STZ +NAD diabetic rats whereas the levels of high density lipoprotein-cholesterol (HDL-C) and serum insulin levels were significantly 
decreased  in STZ + NAD induced diabetic rats The effect of 4-((benzyloxy)amino)-2-hydroxy-4-oxobutanoic acid was compared with 
glibenclamide, a reference drug. Treatment with 4-((benzyloxy) amino)-2-hydroxy-4-oxobutanoic acid and glibenclamide resulted in a 
significant reduction of fasting blood glucose levels with increase in plasma insulin levels in diabetic treated rats. 4-((benzyloxy) amino)-2-
hydroxy-4-oxobutanoic acid also resulted in a significant improvement in serum lipids and lipid peroxidation products. Our results suggest 
the potential role of 4-((benzyloxy) amino)-2-hydroxy-4-oxobutanoic acid in the management of type-2 diabetes mellitus experimental rats. 
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INTRODUCTION 
Diabetes Mellitus (DM), commonly referred as diabetes, is a 
group of metabolic disorders in which the sugar levels are 
high over a prolonged period in blood which results in 
hypoglycemia, lipoprotein abnormalities, raised metabolic 
rate. According to WHO, global prevalence of DM in 2014 
was 9% among adults1.  India is the diabetic capital of the 
world, predicted to have 57.2 million diabetic populations 
by the year 20152. The estimated burden of individuals 
with diabetes in South East Asia aged between 20 to 79 
years was equivalent to 78.3million in 2015, which was 
expected to rise to 140.2 million by 20403. Diabetes is a 
progressive disease and is associated with many 
complications like neuropathy, retinopathy, nephropathy 
and cardiovascular disease.  
At molecular level, insulin resistance is associated 
predominantly with defect in activation and expression of 
proximal molecules of insulin signaling pathway e.g., 
Insulin receptor, Insulin receptor substrate (IRS) etc.4-5 
There are many side effects associated with prolong use of 
insulin and hypoglycemic disease. As incident rate of 
diabetes mellitus continue to rise, there is growing need to 
identify novel antidiabetic agent with less side-effects and 
improved efficacy. About 80 % of world populations use 
the herbal drugs, for treatment of various diseases6. The 
anti-hyperglycemic activity of Eugenia jambolana 
(Botanical name- Syzgium cumini) from its seeds, fruit 
pulp, barkand roots has been well established7-10. 
Sharma et. al has already isolated the active 
antihyperglycemic compound known as alpha hydroxy 
succinamic acid (FIIc)(US Patent number 6,426,826 dated 
6th August 2002; Indian Product Patent number. 2,30,753 
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February 2009) from the fruit pulp of Eugenia jambolana11. 
Therefore, it is expected that succinamic acid derivatives 
will possess antidiabetic and antioxidant properties. Alpha 
hydroxy acids including malic acid, glycolic acid, citric acid, 
tartaric acid, lactic acid and others are group of natural 
acids found in foods. 4-((benzyloxy) amino)-2-hydroxy-4-
oxobutanoic acid is a class of alpha hydroxy acid derivative, 
which is widely found in food, medicine and cosmetic 
industries12. Due to the seasonal barriers and less yield of 
herbal anti-diabetic compound (FIIc) obtained from the 
fruit pulp of E.jambolana, this study was designed to 
synthesize and to assess the anti-hyperglycemic, 
hypolipidemic and antioxidant potential of 4-((benzyloxy) 
amino)-2-hydroxy-4-oxobutanoic acid (succinamic acid 
derivative) in nicotinamide-streptozotocin-induced type-2 
diabetic rats. The structure of the synthesized compound is 
displayed in Fig. 1. 
 
Figure 1: Structure of 4-((benzyloxy)amino)-2-
hydroxy-4-oxobutanoicacid 
MATERIAL AND METHODS 
Chemistry 
Succinamic acid derivative was synthesized according to 
Scheme 1 starting with malic acid. L and D form of malic 
acid are available as hydroxyl carboxylic acid; it fulfills the 
primary condition for selective esterification of malic acid. 
In order to convert malic acid to 2, the hydroxyl group 
present at the α position of carboxy group required for 
selective esterification. Malic acid was alkylated by 
treatment with trifluoroacetic anhydride and methanol 
through a malic anhydride intermediate shown in fig. 2, 
which was in-situ converted to give 3-hydroxy-4-methoxy-
4-oxobutanoic acid(2). Compound 2 was treated with O-
benzylhydroxylamine(3) using amide coupling condition to 
give methyl 4-((benzyloxy)amino)-2-hydroxy-4-
oxobutanoate(4). Compound 5 was obtained from 4 by 
using basic hydrolysis conditions to give 4-((benzyloxy) 
amino)-2-hydroxy-4-oxobutanoic acid (5). Melting points 
of all synthesized compounds were determined on an 
electrothermal apparatus. Malic acid, TFAA, EDC. HCl, 
HOBT, TEA, NaOH were procured from Spectrochem Pvt. 
Ltd., India. All solvents were purified and dried by standard 
methods.
 
 
Fig. 2 
Scheme: 1 
 
Step 1: 
Procedure for synthesis of 3-hydroxy-4-methoxy-4-
oxobutanoic acid (2) Trifluoroacetic anhydride (45 ml) 
was added to L-malic (1) acid (10.0 g, 1 eq) at 00C and 
allowed to stir at rt. After 1.5h, excess of TFAA and TFA 
were distilled off on rotary evaporator at temperature < 30 
°C. The white crystalline compound obtained was cooled to 
0°C and anhydrous methanol (50 mL) was added portion 
wise. The reaction mixture was further allowed to stir at rt 
for 3h.The progress of reaction was monitored by TLC and 
after the completion of reaction, excess methanol was 
distilled off under reduced pressure. The crude compound 
was purified by column chromatography using silica gel 
(60:120 mesh) in 10-40 % EtOAc: Hexane as solvent 
system. The desired compound was obtained in 40% 
EtOAc: Hexane as white solid. m.p. 69-70 0C ; Yield : 50.67 
% ; 1H NMR (400 MHz, DMSO): 12.31 (br s, 1H, -COOH), 
4.33 (t, 1H), 3.62 (s, 3H), 2.62 (d, J=15.57 Hz., 1H, Ha), 2.46 
(d, J=15.57 Hz., 1H, Hb) ; 13C NMR (100 MHz, DMSO) δ: 
174.09, 172.22, 72.02, 63.67, 55.45, 36.03; HRMS (ESI) 
(M+H)+Calcd for C5H8O5: 148.0372, found 148.0367. 
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Step 2: 
Procedure for synthesis of methyl 4-((benzyloxy) 
amino)-2-hydroxy-4-oxobutanoate (4)  
To a stirred solution of 2 (1.0 g, 1 eq) in THF, EDC.HCl (1.5 
eq) was added and reaction mixture was allowed to stir at 
rt for 10 min. Then HOBt (1.5 eq) was added followed by 
the addition of TEA (3.0 eq) and compound 3 (1.2 eq). The 
resultant reaction mixture was allowed to stir at rt for 12 
h. Progress of reaction was monitored by TLC and after the 
completion of reaction, it was diluted with water and 
extracted with EtOAc (3x50 ml). Then organic layer was 
washed with brine, dried over anhydrous NaSO4 and 
concentrated under reduced pressure. The crude product 
was purified by column chromatography using silica gel 
(60-120 mesh) in 10-40 % EtOAc: Hexane as solvent 
system. The desired compound was obtained in 45 % 
EtOAc: hexane as off white solid. m.p. 68-720C; Yield: 49.07 
%; 1H NMR (400 MHz, DMSO-d6): 11.05 (br s, 1H, -
NH),7.37-7.43 (m, 5H), 4.75 (s, 2H), 4.86 (t, 1H), 3.61 (s, 3H), 
2.35 (d, J=5.04 Hz. 1H, Ha), 2.24 (d, J=7.79 Hz., Hb); 13C 
NMR (100 MHz, DMSO) δ: 174.09, 169.22, 133.59, 129.48, 
129.05, 128.46, 78.02, 63.67, 54.55, 36.03. ); HRMS (ESI) 
(M+H)+Calcd for C12H15NO5: 254.0950, found 254.1021. 
 
 
Step 3: 
Procedure for synthesis of 4-((benzyloxy) amino)-2-
hydroxy-4-oxobutanoic acid (5) 
To a stirred solution of 4 (1.0 g, 1 eq) in MeOH, aqueous 
solution of NaOH (5 eq) was added and allowed to stir at rt 
for 6 h. Progress of reaction was monitored by TLC and 
after completion of reaction, the reaction mixture was 
concentrated under reduced pressure.   The reaction 
mixture was acidified with 1N HCl which resulted in the 
formation of solid compound and was filtered through 
sintered funnel, washed with cold H2O and dried under 
high vacuum to give desired compound 5 as off white solid. 
m.p. 79-820C; Yield: 55.32 % ; 1H NMR (400 MHz, DMSO-
d6):11.03 (br s, 1H, -NH),7.39-7.32 (m, 5H), 4.76 (s, 2H), 
4.30 (t, 1H), 2.35 (dd, J=14.20 Hz. 1H, Ha), 2.19 (dd, J=14.21 
Hz. 1H, Hb);13C NMR (100 MHz, DMSO) δ: 172.62, 169.63, 
134.02, 129.46, 129.04, 128.458, 78.019, 63.832, 35.972.; 
HRMS (ESI) (M+H)+Calcd for C11H13NO5: 239.0794, found 
239.0879. 
Biology 
Experimental animals: Male Wistar albino rats (weighing 
220 - 250 grams) were procured from Central Animal 
House of UniversityCollege of Medical Sciences (UCMS), 
University of Delhi, India. The animals were housed in 
standard conditions of temperature (22 ± 2°C) and at 12 
hour light-dark cycle. The rats were fed with commercial 
diet (Hindustan liver Ltd., Mumbai) and water ad libitum. 
The experimental protocol was approved by the 
Institutional Animal Ethical Committee (IAEC), UCMS, 
Delhi, India (UCMS/IAEC/26 granted on 30th December 
2013) 
Induction of diabetes in rats 
Overnight fasted animals were made diabetic by intra-
peritoneal injection of freshly prepared Streptozotocin 
(Sigma Chemical Company, USA) in citrate buffer (0.1 M, 
pH 4.5) at a dose of 45 mg/kg body weight. Nicotinamide at 
a dose of 230 mg/kg body weight was given15 minutes 
prior to STZ injection for the development of stable type 2 
diabetes mellitus13.The control rats were only injected with 
citrate buffer. After 72 h of induction when blood glucose 
was stabilized, fasting blood glucose (FBG) was determined 
and rats having FBG >250 mg/dl were designated as having 
diabetes mellitus and were used in this experiment. The 
experimental period lasted for 4 weeks and day 0 was 
designated as the day when rats were confirmed to be 
diabetic. 
The animals were divided into 4 groups and each group 
consisted of 6 rats: 
 Group A : Healthy control (normal saline) 
 Group B: Diabetic control (normal saline) 
 Group C: Diabetic treated with 4-((benzyloxy)amino)-
2-hydroxy-4-oxobutanoic acid 
 Group D: Diabetic treated with glibenclamide 
1/50 of LD50 was considered as sublethal dose of 4-
((benzyloxy) amino)-2-hydroxy-4-oxobutanoic acid and it 
was used as therapeutic dose in the subsequent work 
which was calculated to be 18 mg/kg b.w. Glibenclamide 
was given as a standard drug orally at a dose of 600µg/kg 
of body weight / day for 4 weeks to group D. 
Acute toxicity study and determination of LD50 
LD50 of the studied compound 4-((benzyloxy) amino)-2-
hydroxy-4-oxobutanoic acid was determined as described 
by Afifi et al14. In this experiment, six groups each of 6 male 
albino rats weighing 180-220 g were used. One group 
serves as control andother groups of mice were orally 
administered the tested compound by gastric tube in 
gradual increasing doses (200, 400, 600, 800 and 1000mg/ 
kg b. w.). After 48 hours of administration, the number of 
dead animals in each group was counted, mean of dead 
animals in two successive doses (z) and the constant factor 
between two successive doses (d) were recorded and LD50 
was calculated as follow: 
LD50 = the highest dose which kill all animals - Σ(z.d)/n 
Where n: number of animals in groups = six animals in 
eachgroup. 
Biochemical parameters: 
Blood was drawn from retro orbital plexus by using micro-
capillary technique from all overnight fasted animals on 
day 1 and afterwards at week 4 of the study. Whole blood 
was drawn for the estimation of glycosylated hemoglobin 
and plasma/serum was separated from blood for the 
estimation of fasting blood glucose, lipid profile, serum 
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insulin levels and oxidative stress parameters. These 
samples were carefully processed and stored in -80 °C deep 
freezer. All the parameters were measured using 
commercially available kits: Plasma fasting blood glucose 
(Centronic, GmbH, Gemany), Glycosylated Hemoglobin 
(Hb1Ac; Biosystems S.A., Costa Brava, Spain), Total serum 
cholesterol (Infinite; Accurex Biomedical, Thane, India), 
Serum triglycerides (Infinite; Accurex Biomedical, Thane, 
India), HDL-Cholesterol (Infinite; Accurex Biomedical, 
Thane, India) Insulin (Ray Biotech Rat ELISA kit, USA) and 
Malondialdehyde (MDA) levels using standard techniques. 
Insulin test was performed using Rayto 2100c microplate 
ELISA reader (Rayto, China). The amount of insulin was 
quantified by sandwich enzyme-linked immunosorbent 
assay (ELISA). The absorbance was measured at 450 nm 
through ELISA plate reader 
Statistical analysis: Two ways ANOVA was applied for the 
comparison of parameters between the groups followed by 
Tukey’s test. Pearson’s coefficient of correlation was 
calculated for all the 4 groups together and separately for 
all the above mentioned parameters. Difference was 
assumed to be significant at the level of p < 0.05. 
RESULTS & DISCUSSION 
Chemistry (Synthesis) 
In this research work, we have synthesized derivative of 
hydroxy succinamic acid with one polar and other side non 
polar as building block for preparation of α-hydroxy acid.3 
Our synthetic strategy starts from the easily available 
compound, malic acid and trifluoroacetiticanhydride, 
which converted into cyclic anhydride intermediate, then 
this cyclic anhydride intermediate on treatment with 
MeOH led to the synthesis of 3-hydroxy-4-methoxy-4-
oxobutanoic (2). Then, this compound was treated with O-
benzylhydroxylamine followed by the amide coupling 
condition to give methyl 4-((benzyloxy) amino)-2-hydroxy-
4-oxobutanoate (4).Then compound (4) was hydrolyzed 
under basic conditions to give target compound 4-
((benzyloxy)amino)-2-hydroxy-4-oxobutanoic acid (5). 
Target compound (5) was synthesized. All synthesized 
compound confirmed by 1H-NMR, 13C-NMR and HRMS data. 
 
 
Biological studies 
For determination of lethal dose LD50 of 4-
((benzyloxy)amino)-2-hydroxy-4-oxobutanoic acid, single 
gradual increasing doses were administered to various 
groups of normal albino rats. The number of dead animals 
in each group was counted after 48 hours of compound 
administration and LD50 was calculated which  was found 
to be 767 mg/kg b.w. Based on this toxicity study, the 
orally therapeutic dose was calculated (18 mg/kg of b.w.) 
which is about1/50 of LD50 which is so far from LD50. 
(Table 1) 
In the present study, a significant improvement was 
observed in glycemic index, serum insulin, lipid profile and 
lipid peroxidation products in 4-((benzyloxy) amino)-2-
hydroxy-4-oxobutanoic acid treated rats. The various 
biochemical parameters has been summarized in Table 2 
& 3 
 
Table 1: Determination of LD50 of 4-((benzyloxy) amino)-2-hydroxy-4-oxobutanoic acid in male albino wistar rats 
Dose (mg/kg b.w.) Total no of 
animals 
No of dead 
animals 
z d ∑(z.d) 
200 6 0 - 200 - 
400 6 1 0.5 200 100 
600 6 2 1.5 200 300 
800 6 3 2.5 200 500 
1000 6 4 3.5 200 700 
1200 6 6 5 200 1000 
z: mean number of dead animals in two successive doses 
d: constant factor between two successive doses 
LD50 = Median lethal dose which kill all animals - Σ(z.d)/n = 1200-2600/6 =767mg /kg b. w. 
1/50 of LD50 is about 18 mg /kg b. w. which was considered as sublethal dose that was used as therapeutic dose in the subsequent 
studies. 
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Table 2: Showing glycemic index and serum insulin levels at week 0 and at week 4 after treatment with 4-((benzyloxy) 
amino)-2-hydroxy-4-oxobutanoic acid and glibenclamide  
 
Parameters 
 
Time points 
 
Group A 
 
Group B 
 
Group C 
 
Group D 
FBG (mg/dl) Week 0 97±6.7 233.2 ± 7.9 a 226 ±7.85b,d 222.4 ±9.6c,b 
Week 4 96±5.64 247.45± 5.64a 124.3± 5.46b,d 118+2.75c,b 
HbA1c % Week 0 5.01±0.12 5.32±0.28a 5.24±0.29b,d 5.38±0.22c,b 
Week 4 5.18±0.10 8.58±0.68a 6.01±0.22b,d 5.94±0.23c,b 
Serum Insulin 
(pmol/L) 
Week 0 15.16±0.64 8.86±0.58a 8.96±0.34b,d 8.67±0.24c,b 
Week 4 15.64±0.56 7.46±0.19a 12.46±0.42b,d 13.12±0.35c,b 
Values are mean ± S.D. (n=6) (p<0.001) 
a= Group A vs Group B, b= Group A vs Group C, c= Group A vs Group D, d= Group B vs Group C 
Effect of 4-((benzyloxy) amino)-2-hydroxy-4-
oxobutanoic acid on fasting blood glucose levels 
FBG levels were measured at week 0 & week 4 for entire 
experimental groups. A significant (p<0.01) decrease in 
FBG levels were observed in 4-((benzyloxy) amino)-2-
hydroxy-4-oxobutanoic acid and glibenclamide treated 
groups as compared to diabetic control rats.  
Effect of 4-((benzyloxy) amino)-2-hydroxy-4-
oxobutanoic acid on HbA1c levels 
The glycosylated Hb (HbA1c) level was significantly 
increased in the diabetic control rats when compared to 
normal control (p<0.001). The HbA1c level was lowered 
significantly in 4-((benzyloxy) amino)-2-hydroxy-4-
oxobutanoic acid and glibenclamide treated groups.  
Effect of 4-((benzyloxy) amino)-2-hydroxy-4-
oxobutanoic acid on serum Insulin levels 
The serum insulin levels in the diabetic control rats was 
found to be 8.86±0.58 pmol/L which was significantly 
decreased (p<0.001) when compared to normal rats. 
However, a significant increase (p<0.01) in serum insulin 
levels in 4-((benzyloxy) amino)-2-hydroxy-4-
oxobutanoic acid and glibenclamide treated groups was 
observed.  
 
Table 3: Showing serum lipids and malonaldialdyhde (MDA) levels at week 0 and at week 4 after treatment with 4-
((benzyloxy) amino)-2-hydroxy-4-oxobutanoic acid and glibenclamide  
 
Parameters 
 
Time points 
 
Group A 
 
Group B 
 
Group C 
 
Group D 
Serum Total Cholesterol (TC) (mg/dl) Week 0 60.55±4.48 61.23±7.66a 62.8±5.38 b,d 60.04±6.34 c,b 
Week 4 61.92±4.32 90.86±6.48a 72.04±6.09 b,d 76.04±4.09 c,b 
Serum Triglycerides (TG) (mg/dl) Week 0 63.8±5.01 65.60±4.45a 64.14±4.8 b,d 67±6.62 c,b 
Week 4 65.8±4.14 104.0±6.26a 82.26±5.01 b,d 86.34±5.01 c,b 
HDL-Cholesterol (HDL-c) (mg/dl) Week 0 38.2±1.68 37.32±1.60a 37.67±1.50 b,d 37.33±1.63 c,b 
Week 4 37.67±1.09 25.17±1.12a 34.80±1.09 b,d 32.80±1.16 c,b 
Malondialdehyde (MDA) (pmol/mg) Week 0 4.2±0.42 4.1±0.25a 4.32±0.22 b,d 4.1±0.36 c,b 
Week 4 4.3±0.26 8.08±0.45a 6.4±0.15 b,d 5.92±0.48 c,b 
Values are mean ± S.D. (n=6) (p<0.001) 
a= Group A vs Group B, b= Group A vs Group C, c= Group A vs Group D, d= Group B vs Group C 
Effect of 4-((benzyloxy) amino)-2-hydroxy-4-
oxobutanoic acid on serum TC 
The mean serum total cholesterol levels of normal control 
rats was 60.56 ± 4.48 mg/dl, which was significantly (p < 
0.001) increased to 90.86 ± 6.48 mg/dl in the diabetic 
control rats (Table 3). This increased serum TC level was 
significantly decreased by treatment with 4-
((benzyloxy)amino)-2-hydroxy-4-oxobutanoic acid and 
glibenclamide 
Effect of 4-((benzyloxy) amino)-2-hydroxy-4-
oxobutanoic acid on serum TG 
The mean serum triglyceride level of normal control rats 
was 64.80 ± 4.15 mg/dl, which significantly (p < 0.001) 
increased to 104.00 ± 6.26 mg/dl in the diabetic control 
rats (Table 3). This increased serum triglyceride level 
significantly decreased by treatment with 4-((benzyloxy) 
amino)-2-hydroxy-4-oxobutanoic acid and glibenclamide.  
Effect of 4-((benzyloxy) amino)-2-hydroxy-4-
oxobutanoic acid on serum HDL-c 
Induction of diabetes caused significant (p < 0.001) 
decrease in serum HDL-cholesterol levels of 38.20± 81.68 
mg/dl to 25.17 ± 1.12 mg/dl when compared against 
normal control rats (Table 3). Treatment with 4-
((benzyloxy) amino)-2-hydroxy -4-oxobutanoic acid 
produced significant increase in the serum HDL-cholesterol 
levels. 
Effect of 4-((benzyloxy) amino)-2-hydroxy-4-
oxobutanoic acid on Malondialdehyde levels 
Compared to normal control rats, diabetic control rats 
showed a significant increase in MDA levels (p<0.001). 4-
((benzyloxy)amino)-2-hydroxy-4-oxobutanoic acid and 
glibenclamide treated groups showed a significant 
decrease in the MDA levels when compared to diabetic 
control rats (p<0.001). 
In our study, we have observed that 4((benzyloxy)amino)-
2-hydroxy-4-oxobutanoic acid) decreases plasma glucose 
and increased plasma insulin in streptozotocin–
nicotinamide induced diabetic rats. The possible 
mechanism of action of 4((benzyloxy)amino)-2-hydroxy-4-
oxobutanoic acid) that can be correlated with the  effect of 
sulphonylureas that promote insulin secretion by closure 
of K+- ATP channels, membrane depolarization and 
stimulation of Ca2+ influx, an initial key step in insulin 
secretion15-16. 
 In diabetes hyerpglycemia is accompanied with 
dyslipidemia i.e., characterized by increase in TC, TG & fall 
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in HDL-c. The increased serum lipids (TG & TC) which may 
be due to due to the increased mobilization of free fatty 
acids from peripheral deposits, since insulin inhibits 
hormone sensitive lipase17.  This altered serum lipid profile 
was significantly (p<0.001) revered back to normal after 
treatment with 4((benzyloxy) amino)-2-hydroxy-4-
oxobutanoic acid).  This suggests its potential as a lipid 
lowering agent.  
It has been found that the rate of formation of 
Malonaldialdehyde (MDA) is significantly increased in 
diabetic rats compared to healthy rats18. Several studies 
have confirmed the involvement of free radicals in the 
genesis of diabetes mellitus and their role in the induction 
of lipid peroxidation during diabetes19.  The possible 
mechanism that can be correlated would be the diffusion of 
lipid peroxidation products from the site of tissue damage 
and therefore can be measured in plasma20.  
Our findings indicate that 4((benzyloxy) amino)-2-
hydroxy-4-oxobutanoic acid) possesses potent antioxidant 
properties due to its inhibition of the formation of lipid 
peroxidation end-product, MDA, in the type 2 diabetic rats.  
CONCLUSION 
In this study, we have found that the novel synthetic 4-
((benzyloxy)amino)-2-hydroxy-4-oxobutanoic acid has 
anti-hyperglycemic, hypolipidemic and antioxidant 
potentials in STZ +NAD induced type 2 diabetic rats. These 
effects may be due to insulinogenic action and 
extrapancreatic effects in addition to the enhancing action 
on the antioxidant defense system. However, further 
clinical studies are required to assess the safety and 
efficacy of the of 4-((benzyloxy) amino)-2-hydroxy-4-
oxobutanoic acid and to elucidate its role a potent 
antidiabetic agent. 
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